Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
48.06
-0.24 (-0.50%)
Nov 20, 2026, 2:08 PM EST - Market open
Travere Therapeutics Employees
Travere Therapeutics had 497 employees as of December 31, 2025. The number of employees increased by 112 or 29.09% compared to the previous year. That makes Travere Therapeutics the 20,175th largest employer in the world and 2,673rd in the United States.
Employees
497
Change (1Y)
112
Growth (1Y)
29.09%
Revenue / Employee
$1,309,928
Profits / Employee
-$244,481
Market Cap
4.61B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 497 | 112 | 29.09% |
| Dec 31, 2024 | 385 | 5 | 1.32% |
| Dec 31, 2023 | 380 | -82 | -17.75% |
| Dec 31, 2022 | 462 | 152 | 49.03% |
| Dec 31, 2021 | 310 | 48 | 18.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Ionis Pharmaceuticals | 1,480 |
| PTC Therapeutics | 991 |
| CRISPR Therapeutics AG | 393 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| Edgewise Therapeutics | 133 |
| Definium Therapeutics | 106 |
TVTX News
- 3 days ago - Travere Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 4 days ago - Travere Therapeutics Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 7 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Travere Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 10 days ago - Travere Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 14 days ago - Travere Therapeutics price target lowered to $86 from $90 at JPMorgan - TheFly
- 16 days ago - Travere Therapeutics price target lowered to $78 from $89 at Guggenheim - TheFly
- 16 days ago - Travere Therapeutics price target raised to $72 from $70 at Canaccord - TheFly